-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, the local CRO pharmaceutical company Pharmaron announced that the company signed an asset purchase agreement with Noramco in the United States to acquire the latter's API production base in Coventry, Rhode Island, United Stat.
This transaction is expected to meet the usual practi.
Completion after closing conditio.
According to reports, the Coventry production base is equipped with complete production facilities, which can provide cGMP API production services from pilot to ton commercial sca.
Pharmaron Chemical is a full-process integrated pharmaceutical R&D service platform with operations all over the wor.
It is committed to assisting customers in accelerating drug innovation and providing full-process integrated drug research, development and production services from drug discovery to drug developme.
According to the main business types, it can be divided into four service sectors: laboratory services, CMC (small molecule CDMO) services, clinical research services, macromolecules and cell and gene therapy servic.
The company said the acquisition will help it build chemical and manufacturing services capabilities in the United Stat.
In recent years, Pharmaron has actively deployed overseas marke.
In addition to the acquisition of the API production base in Coventry, Rhode Island, USA, for example, in March 2021, Pharmaron announced the acquisition of AbbVie’s biopharmaceuticals in the UK for US$118 milli.
Production plant, this transaction aims to build a large CGT service platform from preclinical research, product development to commercial production; in January 2021, Pharmaron announced the successful acquisition of Recipharm's Aesica Pharmaceuticals in Cramlington, .
The Cramlington production base is located in Newcastle, UK, with a production capacity of more than 100 cubic meters of reactors, and can provide cGMP API production services from pilot to ton commercial scale; in November 2020, Kanglong Chemical acquired Absorption Systems for 942 million yuan 100% equity of LLC and its wholly-owned subsidiaries ASC and ASB,e.
In addition to Pharmaron, there are also some local CRO pharmaceutical companies aiming to actively deploy overse.
For example, WuXi PharmaTech recently released the "Proposal on the Company's Plan for Additional H Share.
This private increase is intended to provide global customers with a reliable supply chain and build new production capacity in the United States, Europe and Singapo.
It is reported that WuXi has been actively building and acquiring overseas bases in recent yea.
The current construction project is 75 billion yu.
It is building a production base for preparations and APIs in Delaware, U.
It is expected to be put into operation in 202 The second base built in the United States is also the eighth R&D and production base deployed global.
In August 2021, WuXi AppTec’s subsidiary Hequan Pharmaceutical announced that the acquisition of Bristol-Myers Squibb’s Couvet preparation production base in Switzerland has been successfully complet.
After completing the acquisition of this GMP preparation production base, it will be able to commercialize capsules and tablets on a large scale, becoming Hequan Pharmaceutical's first production base in Euro.
In addition, the new high-end testing laboratory expanded by WuXi Pharma in the Philadelphia base of the United States has been officially put into operati.
Completed the acquisition of OXGENE, a UK-based gene therapy technology company, as the first R&D and production base of WuXiQ in Euro.
From the perspective of the industry, CXO is a typical capital-intensive and talent-intensive indust.
For the enterprises in the layout, the expansion of the scale can not only greatly improve the company's ability to undertake business, but also enhance the company's industrial stat.
The acquisition of Pharmaron's API production base in the United States is a continuation of the company's overseas expansion, and it is also a continuous acceleration of the industry's infl.
Click to enter the exhibition page
This transaction is expected to meet the usual practi.
Completion after closing conditio.
According to reports, the Coventry production base is equipped with complete production facilities, which can provide cGMP API production services from pilot to ton commercial sca.
Pharmaron Chemical is a full-process integrated pharmaceutical R&D service platform with operations all over the wor.
It is committed to assisting customers in accelerating drug innovation and providing full-process integrated drug research, development and production services from drug discovery to drug developme.
According to the main business types, it can be divided into four service sectors: laboratory services, CMC (small molecule CDMO) services, clinical research services, macromolecules and cell and gene therapy servic.
The company said the acquisition will help it build chemical and manufacturing services capabilities in the United Stat.
In recent years, Pharmaron has actively deployed overseas marke.
In addition to the acquisition of the API production base in Coventry, Rhode Island, USA, for example, in March 2021, Pharmaron announced the acquisition of AbbVie’s biopharmaceuticals in the UK for US$118 milli.
Production plant, this transaction aims to build a large CGT service platform from preclinical research, product development to commercial production; in January 2021, Pharmaron announced the successful acquisition of Recipharm's Aesica Pharmaceuticals in Cramlington, .
The Cramlington production base is located in Newcastle, UK, with a production capacity of more than 100 cubic meters of reactors, and can provide cGMP API production services from pilot to ton commercial scale; in November 2020, Kanglong Chemical acquired Absorption Systems for 942 million yuan 100% equity of LLC and its wholly-owned subsidiaries ASC and ASB,e.
In addition to Pharmaron, there are also some local CRO pharmaceutical companies aiming to actively deploy overse.
For example, WuXi PharmaTech recently released the "Proposal on the Company's Plan for Additional H Share.
This private increase is intended to provide global customers with a reliable supply chain and build new production capacity in the United States, Europe and Singapo.
It is reported that WuXi has been actively building and acquiring overseas bases in recent yea.
The current construction project is 75 billion yu.
It is building a production base for preparations and APIs in Delaware, U.
It is expected to be put into operation in 202 The second base built in the United States is also the eighth R&D and production base deployed global.
In August 2021, WuXi AppTec’s subsidiary Hequan Pharmaceutical announced that the acquisition of Bristol-Myers Squibb’s Couvet preparation production base in Switzerland has been successfully complet.
After completing the acquisition of this GMP preparation production base, it will be able to commercialize capsules and tablets on a large scale, becoming Hequan Pharmaceutical's first production base in Euro.
In addition, the new high-end testing laboratory expanded by WuXi Pharma in the Philadelphia base of the United States has been officially put into operati.
Completed the acquisition of OXGENE, a UK-based gene therapy technology company, as the first R&D and production base of WuXiQ in Euro.
From the perspective of the industry, CXO is a typical capital-intensive and talent-intensive indust.
For the enterprises in the layout, the expansion of the scale can not only greatly improve the company's ability to undertake business, but also enhance the company's industrial stat.
The acquisition of Pharmaron's API production base in the United States is a continuation of the company's overseas expansion, and it is also a continuous acceleration of the industry's infl.
Click to enter the exhibition page
